Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Empagliflozin for Kidney Transplant Recipients
Recruiting3 awardsPhase 4
Pittsburgh, Pennsylvania
This trial tested whether a drug could improve health and quality of life for veterans with kidney disease by reducing the risk of cardiovascular disease. Results showed it had a kidney and heart protective effect, improving patient outcomes.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.